Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.


Journal

Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 6 2 2021
medline: 28 9 2021
entrez: 5 2 2021
Statut: ppublish

Résumé

Coronary artery abnormalities (CAAs) still occur in patients with Kawasaki disease receiving intensified treatment with corticosteroids. We aimed to determine the risk factors of CAA development and resistance to intensified treatment in Post RAISE (Prospective Observational Study on Stratified Treatment With Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease)-the largest prospective cohort of Kawasaki disease patients to date. In Post RAISE, 2648 consecutive patients with Kawasaki disease were enrolled. The present study analyzed 724 patients predicted to be intravenous immunoglobulin (IVIG) nonresponders (Kobayashi score ≥5) who received intensified treatment consisting of IVIG plus prednisolone. The association between the baseline characteristics and CAA at 1 month after disease onset was examined. The association between the baseline characteristics and treatment resistance was also investigated. Maximum In Post RAISE, younger age at fever onset, a larger maximum

Sections du résumé

BACKGROUND
Coronary artery abnormalities (CAAs) still occur in patients with Kawasaki disease receiving intensified treatment with corticosteroids. We aimed to determine the risk factors of CAA development and resistance to intensified treatment in Post RAISE (Prospective Observational Study on Stratified Treatment With Immunoglobulin Plus Steroid Efficacy for Kawasaki Disease)-the largest prospective cohort of Kawasaki disease patients to date.
METHODS
In Post RAISE, 2648 consecutive patients with Kawasaki disease were enrolled. The present study analyzed 724 patients predicted to be intravenous immunoglobulin (IVIG) nonresponders (Kobayashi score ≥5) who received intensified treatment consisting of IVIG plus prednisolone. The association between the baseline characteristics and CAA at 1 month after disease onset was examined. The association between the baseline characteristics and treatment resistance was also investigated.
RESULTS
Maximum
CONCLUSIONS
In Post RAISE, younger age at fever onset, a larger maximum

Identifiants

pubmed: 33541111
doi: 10.1161/CIRCOUTCOMES.120.007191
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Immunoglobulins, Intravenous 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007191

Auteurs

Koichi Miyata (K)

Department of Cardiology (K.M., M. Miura), Tokyo Metropolitan Children's Medical Center, Japan.

Masaru Miura (M)

Department of Cardiology (K.M., M. Miura), Tokyo Metropolitan Children's Medical Center, Japan.

Tetsuji Kaneko (T)

Clinical Research Support Center (T.K., Y.M.), Tokyo Metropolitan Children's Medical Center, Japan.
Teikyo Academic Research Center, Teikyo University, Tokyo, Japan (T.K.).

Yoshihiko Morikawa (Y)

Clinical Research Support Center (T.K., Y.M.), Tokyo Metropolitan Children's Medical Center, Japan.

Hiroshi Sakakibara (H)

Department of General Pediatrics (H.S., T.M.), Tokyo Metropolitan Children's Medical Center, Japan.

Takahiro Matsushima (T)

Department of General Pediatrics (H.S., T.M.), Tokyo Metropolitan Children's Medical Center, Japan.

Masahiro Misawa (M)

Department of Pediatrics, Tokyo Metropolitan Bokutoh Hospital, Japan (M. Misawa).

Tsutomu Takahashi (T)

Department of Pediatrics, Saiseikai Utsunomiya Hospital, Tochigi, Japan (T. Takahashi).

Maki Nakazawa (M)

Department of Pediatrics, National Hospital Organization Saitama National Hospital, Saitama, Japan (M.N.).

Takatoshi Tsuchihashi (T)

Department of Pediatrics, Kawasaki Municipal Hospital, Kanagawa, Japan (T. Tsuchihashi).

Yukio Yamashita (Y)

Department of Pediatrics, Yokohama Municipal Citizen's Hospital, Kanagawa, Japan (Y.Y.).

Toshimasa Obonai (T)

Department of Pediatrics, Tama-Hokubu Medical Center, Tokyo, Japan (T.O.).

Michiko Chiga (M)

Department of Pediatrics, Tokyo Metropolitan Ohtsuka Hospital, Japan (M.C.).

Naoaki Hori (N)

Department of Pediatrics, Ota Memorial Hospital, Gunma, Japan (N.H.).

Osamu Komiyama (O)

Department of Pediatrics, National Hospital Organization Tokyo Medical Center, Japan (O.K.).

Hiroyuki Yamagishi (H)

Department of Cardiology (K.M., M. Miura), Tokyo Metropolitan Children's Medical Center, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH